{"id":44664,"date":"2022-06-03T15:02:49","date_gmt":"2022-06-03T13:02:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/"},"modified":"2022-06-03T15:02:49","modified_gmt":"2022-06-03T13:02:49","slug":"investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/","title":{"rendered":"Investigators from US Oncology Research, The US Oncology Network and Ontada Present Data Highlighting Key Advances and Insights at the 2022 American Society of Clinical Oncology Annual Meeting"},"content":{"rendered":"
\n

\nKey research highlights include presentations on lung and ovarian cancers, value-based care, health technologies and health disparities<\/i>\n<\/p>\n

<\/a><\/p>\n

THE WOODLANDS, Texas–(BUSINESS WIRE)–During the scientific program of the 2022 American Society of Clinical Oncology (ASCO<\/a>) Annual Meeting, principal investigators from US Oncology Research<\/a>, The US Oncology Network <\/a>(The Network) and Ontada<\/a>\u00ae will present detailed results from more than 80 studies. Presentations include 10 oral sessions on topics including lung and ovarian cancers, as well as research involving value-based care and the use of health technologies. The ASCO Annual Meeting, a leading conference delivering the latest in cancer science to the global community, will be held June 3-7, 2022 in Chicago.\n<\/p>\n

\n\u201cThe oncology community is constantly transforming, and past discoveries provide rationale for the community structures we have today, but new challenges, like changes in the healthcare landscape, will always present themselves,\u201d said Robert L. Coleman, MD, chief scientific officer, US Oncology Research. \u201cThe strengths of community-based research and dedication to improving patients’ outcomes and cancer care experience provide the tenacity needed to turn these challenges into opportunities. Our team of community-based researchers are committed to advancing research, offering ways for patients to receive care from virtual locations, and making access to leading treatments possible for a myriad of patients more than ever before.\u201d\n<\/p>\n

\nMYLUNG Consortium Data to be Highlighted in Two Presentations<\/b>\n<\/p>\n

\nIncluded in the research presentations during this year\u2019s meeting will be findings from Protocol 2 of the M<\/b>olecularly<\/b> Informed L<\/b>ung Cancer Treatment in a Commu<\/b>nity Cancer N<\/b>etwork: A Prag<\/b>matic Consortium\u2122 (MYLUNG Consortium<\/a>) clinical trial platform in non-small cell lung cancer (Abstract #1503), which will be presented during an oral session by Elizabeth Koselke, PharmD, BCOP, senior clinical pharmacist with The Network. Protocol 2 of the study platform included an examination of an oncology clinical pharmacist on the research team and the impact on clinical trial enrollment. The abstract \u201cImpact of oncology clinical pharmacist intervention on clinical trial enrollment in The US Oncology Network\u2019s MYLUNG Consortium<\/a>,\u201d will be featured in the \u201cCare Delivery and Regulatory Policy\u201d session on Monday, June 6 at 4 p.m.\n<\/p>\n

\n\u201cThis is one of the first studies that looked at the effectiveness of pharmacists in this role,\u201d said Koselke. \u201cPharmacists are uniquely positioned to make an impact on all aspects of care, including potentially identifying a patient who may qualify for a clinical study. Enrolling clinical studies has become more challenging, and community research teams need to be more efficient when identifying potential candidates in order to generate meaningful advances at a faster rate. Our hope is that the impact seen within the MYLUNG Consortium will advance how we think and assemble clinical research teams.\u201d\n<\/p>\n

\nIn addition to the oral presentation, Nicholas Robert, MD, chief medical officer of Ontada, will lead a poster presentation (Abstract #9004) from a retrospective study of MYLUNG Consortium Protocol 1. The abstract, \u201cPredictors of biomarker testing among patients (pts) with metastatic non-small cell lung cancer (mNSCLC)<\/a>,\u201d analyzes the impact of clinical and\/or social factors (such as race, histology and clinical practice size) on undertested populations. These data will be presented during the \u201cLung Cancer\u2014Non-Small Cell Metastatic\u201d session, which will be held Monday, June 6 at 8 a.m.\n<\/p>\n

\nAdditional Featured Research Selected for Presentation<\/b>\n<\/p>\n

\nAn oral presentation (Abstract #LBA5500) on a phase 3 study evaluating rucaparib monotherapy titled, \u201cATHENA\u2013MONO (GOG-3020\/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer<\/a>,\u201d was co-authored by Dr. Coleman. These data will be presented during the \u201cGynecologic Cancer\u201d session on Monday, June 6 at 8 a.m.\n<\/p>\n

\n\u201cSurvivorship of women with advanced ovarian cancer has improved, primarily the result of two key agents, bevacizumab and the Poly (ADP-ribose) polymerase (PARP) inhibitors. In the ATHENA trial, we demonstrate the substantial efficacy and safety of a third agent (rucaparib) for primary maintenance treatment,\u201d said Dr. Coleman. \u201cOur team looks forward to presenting our findings involving PARP inhibitors and immune checkpoint inhibitors and their potential as therapeutic options for patients in this population.\u201d\n<\/p>\n

\nAlexander I. Spira, MD, PhD, FACP<\/a>, director of the thoracic and Phase I program for Virginia Cancer Specialists<\/a>, a practice in The Network, will have an oral presentation (Abstract #9002) on the effect of adagrasib (MRTX849) in patients with NSCLC titled, \u201cKRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced\/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C<\/sup> mutation<\/a>.\u201d These data will be presented during the \u201cLung Cancer\u2014Non-Small Cell Metastatic\u201d session on Friday, June 3 at 1:24 p.m.\n<\/p>\n

\nAdditional key NSCLC data presentations involving Dr. Spira\u2019s research include a late breaking abstract (#LBA9009) titled \u201cActivity of adagrasib (MRTX849) in patients with KRASG12C<\/sup>-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial<\/a>,\u201d which is being held during the \u201cIncluding the Excluded: Advancing Care for All Patients With Lung Cancer\u201d clinical symposium on Monday, June 6 at 4:30 p.m. Dr. Spira was also involved in the research featured in (Abstract #9008), \u201cAmivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study<\/a>,\u201d selected for oral presentation during the \u201cLung Cancer\u2014Non-Small Cell Metastatic\u201d session, which will be held on Friday, June 3 at 3:24 p.m.\n<\/p>\n

\n\u201cImmunotherapy research will ultimately lead to greater knowledge and more precise treatments for patients,\u201d said Dr. Spira. \u201cThere is still so much to learn in the area of precision oncology and targeted therapies in NSCLC, and we are constantly working towards ways to develop new and effective therapies that can create better outcomes for patients. The vital research showcased in this clinical symposium and oral presentations on the effect of adagrasib (MRTX849) and amivantamab in patients with NSCLC will help inform the clinical development of these targeted therapies and explain their potential clinical utility and promise.\u201d\n<\/p>\n

\nFeatured Health Technology-Related Research<\/b>\n<\/p>\n

\nAn oral presentation (Abstract #1507) evaluating health technologies and their impact on quality of care and health disparities was co-authored by Debra Patt, MD, PhD, MBA<\/a>, executive vice president of public policy, payer relations and strategic initiatives at Texas Oncology<\/a>, a practice in The Network. The presentation titled, \u201cEvaluating mass implementation of digital health solutions to improve quality and reduce disparities in a large multisite community oncology practice<\/a>,\u201d will be presented during the \u201cCare Delivery and Regulatory Policy\u201d session on Monday, June 6 at 5:12 p.m.\n<\/p>\n

\n\u201cDigital health solutions engage patients with our clinical teams and improve patient care,\u201d said Dr. Patt. \u201cThese solutions reduce response time for symptomatic patients and improve transparency and health literacy improving the partnership between our clinical teams and the patients we serve. Digital health solutions are of great value for all patients, especially those classified as \u2018at risk\u2019. I am grateful to be part of a practice leading some of these important efforts.\u201d\n<\/p>\n

\nAn abstract (#1521) evaluating the usage of a machine learning (ML) model titled \u201cThe initial outcome of deploying a mortality prediction tool at community oncology practices<\/a>,<\/span>\u201d will be presented during the \u201cCare Delivery and Regulatory Policy\u201d poster session. The ML model predicted 90-day mortality risk for patients with metastatic cancer and was designed to facilitate earlier end-of-life discussions, including hospice care, with the patients. These results, researched by members of The US Oncology Network, will be delivered on Saturday, June 4 at 1:15 p.m.\n<\/p>\n

\n\u201cAligning care at the end of life with patients\u2019 goals and values helps reduce the likelihood of undesirable hospitalization, ICU stays and side effects of therapy,\u201d said Ping Ye, PhD, a senior data scientist for The Network. \u201cWe deployed a predictive mortality tool to The Network practices to help physicians proactively initiate care discussions earlier with identified patients, allowing them access to care aligned with their wishes as they near life\u2019s final stages.\u201d\n<\/p>\n

\nYou can find the full schedule of affiliated data presentations from US Oncology Research, The US Oncology Network and Ontada including author details, here<\/a>. For more information or to interview a trial investigator, contact Claire Crye at 281.825.9927 or Claire.Crye@usoncology.com<\/a>, Edie DeVine at 209.814.9564 or Edie.DeVine@gcihealth.com<\/a>, or Ryan Mathre at 651.335.2338 or Ryan.Mathre@mckessson.com<\/a>.\n<\/p>\n

\nAbout The US Oncology Network<\/b>\n<\/p>\n

\nEvery day, The US Oncology Network<\/a> (The Network) helps more than 1,400 independent physicians deliver value-based, integrated care to patients \u2014 close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides practices with access to coordinated resources, best business practices, and the experience, infrastructure, and support of McKesson Corporation<\/a>. This collaboration allows the providers in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere.\n<\/p>\n

\nAbout US Oncology Research<\/b>\n<\/p>\n

\nUS Oncology Research<\/a> draws from a network of experienced investigators and dedicated clinical staff who specialize in oncology clinical trials. US Oncology Research serves approximately 60 research sites and 170 locations, managing about 500 active trials at any given time. For the past 20 years, physicians in the research network have enrolled more than 91,000 patients in approximately 2,000 trials and have played a role in over 100 FDA-approved cancer therapies. US Oncology Research is supported by McKesson Corporation<\/a>.\n<\/p>\n

\nAbout Ontada<\/b>\n<\/p>\n

\nOntada<\/a>\u00ae is an oncology real-world data and evidence, clinical education and provider technology business dedicated to transforming the fight against cancer. Part of McKesson Corporation<\/a>, we support science through our data, technology, and channels, which accelerate innovation for life sciences companies, support the education of community oncology providers and advance patient care. Together with our partners, we improve the lives of cancer patients. For more information, visit ontada.com<\/a> or follow @OntadaOncology<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nUS Oncology Research
\n
Claire Crye, Public Relations
\n
281.825.9927 claire.crye@usoncology.com<\/a>\n<\/p>\n

\nGCI Health on behalf of US Oncology Research
\n
Edie DeVine, Public Relations
\n
209.814.9564 edie.devine@gcihealth.com<\/a>\n<\/p>\n

\nOntada
\n
Ryan Mathre, Public Relations
\n
651.335.2338 ryan.mathre@mckesson.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Key research highlights include presentations on lung and ovarian cancers, value-based care, health technologies and health disparities THE WOODLANDS, Texas–(BUSINESS WIRE)–During the scientific program of the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, principal investigators from US Oncology Research, The US Oncology Network (The Network) and Ontada\u00ae will present detailed results from more … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44664","6":"format-standard","7":"category-industry"},"yoast_head":"\nInvestigators from US Oncology Research, The US Oncology Network and Ontada Present Data Highlighting Key Advances and Insights at the 2022 American Society of Clinical Oncology Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investigators from US Oncology Research, The US Oncology Network and Ontada Present Data Highlighting Key Advances and Insights at the 2022 American Society of Clinical Oncology Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Key research highlights include presentations on lung and ovarian cancers, value-based care, health technologies and health disparities THE WOODLANDS, Texas–(BUSINESS WIRE)–During the scientific program of the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, principal investigators from US Oncology Research, The US Oncology Network (The Network) and Ontada\u00ae will present detailed results from more ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-03T13:02:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220603005154\/en\/308083\/21\/USOR.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Investigators from US Oncology Research, The US Oncology Network and Ontada Present Data Highlighting Key Advances and Insights at the 2022 American Society of Clinical Oncology Annual Meeting\",\"datePublished\":\"2022-06-03T13:02:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\\\/\"},\"wordCount\":1649,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220603005154\\\/en\\\/308083\\\/21\\\/USOR.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\\\/\",\"name\":\"Investigators from US Oncology Research, The US Oncology Network and Ontada Present Data Highlighting Key Advances and Insights at the 2022 American Society of Clinical Oncology Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220603005154\\\/en\\\/308083\\\/21\\\/USOR.jpg\",\"datePublished\":\"2022-06-03T13:02:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220603005154\\\/en\\\/308083\\\/21\\\/USOR.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220603005154\\\/en\\\/308083\\\/21\\\/USOR.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investigators from US Oncology Research, The US Oncology Network and Ontada Present Data Highlighting Key Advances and Insights at the 2022 American Society of Clinical Oncology Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investigators from US Oncology Research, The US Oncology Network and Ontada Present Data Highlighting Key Advances and Insights at the 2022 American Society of Clinical Oncology Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Investigators from US Oncology Research, The US Oncology Network and Ontada Present Data Highlighting Key Advances and Insights at the 2022 American Society of Clinical Oncology Annual Meeting - Pharma Trend","og_description":"Key research highlights include presentations on lung and ovarian cancers, value-based care, health technologies and health disparities THE WOODLANDS, Texas–(BUSINESS WIRE)–During the scientific program of the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, principal investigators from US Oncology Research, The US Oncology Network (The Network) and Ontada\u00ae will present detailed results from more ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-03T13:02:49+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220603005154\/en\/308083\/21\/USOR.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Investigators from US Oncology Research, The US Oncology Network and Ontada Present Data Highlighting Key Advances and Insights at the 2022 American Society of Clinical Oncology Annual Meeting","datePublished":"2022-06-03T13:02:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/"},"wordCount":1649,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220603005154\/en\/308083\/21\/USOR.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/","name":"Investigators from US Oncology Research, The US Oncology Network and Ontada Present Data Highlighting Key Advances and Insights at the 2022 American Society of Clinical Oncology Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220603005154\/en\/308083\/21\/USOR.jpg","datePublished":"2022-06-03T13:02:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220603005154\/en\/308083\/21\/USOR.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220603005154\/en\/308083\/21\/USOR.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/investigators-from-us-oncology-research-the-us-oncology-network-and-ontada-present-data-highlighting-key-advances-and-insights-at-the-2022-american-society-of-clinical-oncology-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Investigators from US Oncology Research, The US Oncology Network and Ontada Present Data Highlighting Key Advances and Insights at the 2022 American Society of Clinical Oncology Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44664"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44664\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44664"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44664"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}